Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS

https://doi.org/10.17749/2070-4909.2015.8.2.055-061

Full Text:

Abstract

Type 2 diabetes mellitus (T2DM) is one the socially important diseases in the Russian Federation (RF). Dipeptidyl peptidase-4 (DPP-4) inhibitors alogliptin, vildagliptin, linagliptin, saxagliptin and sitagliptin are registered in the RF and included in both russian and international modern guidelines on T2DM.

Objective: to conduct a systematical review on clinical efficacy and safety of alogliptin in comparison with other DPP-4 inhibitors in adults with T2DM.

Methods. We performed a search on efficacy and safety of alogliptin compared with vildagliptin, linagliptin, saxagliptin and sitagliptin in two electronic databases: Cochrane library and Medline up to June 15th, 2015. We also searched reference lists of the relevant articles. Methodological quality of five included articles was assessed.

Results. Patients on alogliptin plus metformin achieved HbA1c <7% more frequently than those treated with saxagliptin plus metformin: odds ratio (OR) 6.41, 95% confidence interval (CI) (3.15; 11.98) vs. 2.17, 95% CI (1.56; 2.95). Indirect comparison of alogliptin vs. saxagliptin or sitagliptin is not appropriate due to the differences in age and prior cardiovascular diseases severity in patients with T2DM, included in randomized controlled trials (RCT) EXAMINE, SAVOR-TIMI 53 and TECOS.

Conclusion. There were no differences in efficacy in T2DM between alogliptin and other DPP-4 inhibitors, apart from in patients on alogliptin plus metformin who achieved HbA1c <7% more frequently than those treated with saxagliptin plus metformin. Indirect comparison of safety of alogliptin vs. saxagliptin or sitagliptin is not appropriate due to the differences in population of T2DM patients included in relevant RCTs; indirect comparison of safety alogliptin vs. vildagliptin or linagliptin is impossible due to the absence of the evidence base.

About the Authors

Georgii Rubenovich Khachatryan
Russian Presidential Academy of National Economy and Public Administration
Russian Federation

researcher, 

Vernadskogo prospect, 82-1, Moscow, 119571



Vladislav Sergeevich Dombrovskii
Russian Presidential Academy of National Economy and Public Administration
Russian Federation

researcher,

Vernadskogo prospect, 82-1, Moscow, 119571



References

1. Dedov I., Shestakova M., Galstyan G. et al. Sakharnyi diabet. 2015; 18 (1S): 1-112. DOI: 10.14341/DM20151S1-112.

2. Rebrova O., Goryainov S. Meditsinskie tekhnologii. Otsenka i vybor. 2013; 4 (14): 8-14.

3. Rebrova O., Fedyaeva V., Khachatryan G. Meditsinskie tekhnologii. Otsenka i vybor. 2015; 1 (19): 9-17.

4. Rosstat. Incidence of socially significant illnesses. URL: http://www.gks.ru/free_doc/new_site/population/zdrav/zdr2-2.xls (accessed 15.07.15).

5. American Diabetes Association. Standards of medical care in diabetes 2015. Diabetes Care. Jan 2015; 38 (1).

6. Bucher H.C., Gordon H.G., Lauren E.G., Walter S.D. The Results of Direct and Indirect Treatment Comparisons in Meta-Analysis of Randomized Controlled Trials. J Clin Epidemiol. 1997 Jun; 50 (6): 683-91.

7. Craddy P., Palin H.J., Johnson K.I. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther. 2014 Jun; 5 (1): 1-41. DOI: 10.1007/s13300-014-0061-3. Epub 2014 Mar 25.

8. Flodgren G., Eccles M.P., Shepperd S. et al. An overview of reviews evaluating the effectiveness of financial incentives in changing healthcare professional behaviours and patient outcomes. Cochrane Database of Systematic Reviews. 2011; 7. Art. No.: CD009255. DOI: 10.1002/14651858.CD009255.

9. Green J.B., Bethel M.A., Armstrong P.W. et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015 Jul 16; 373 (3): 232-42. DOI: 10.1056/NEJMoa1501352. Epub 2015 Jun 8.

10. Jansen J.P., Trikalinos T., Cappelleri J.C. et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014 Mar; 17 (2): 157-73. DOI: 10.1016/j.jval.2014.01.004.

11. Monami M., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014 Jul; 24 (7): 689-97. DOI: 10.1016/j.numecd.2014.01.017. Epub 2014 Mar 5.

12. Scirica B.M., Bhatt D.L., Braunwald E. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3; 369 (14): 1317-26. DOI: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.

13. Scirica B.M., Braunwald E., Raz I. et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014 Oct 28; 130 (18): 1579-88. DOI: 10.1161/CIRCULATIONAHA.114.010389. Epub 2014 Sep 4.

14. Shea B.J., Grimshaw J.M., Wells G.A. et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007 Feb 15; 7: 10.

15. Song F., Altman D.G., Glenny A.M., et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta analyses. BMJ. 2003 Mar 1; 326 (7387): 472.

16. White W.B., Cannon C.P., Heller S.R. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 3; 369 (14): 1327-35. DOI: 10.1056/NEJMoa1305889. Epub 2013 Sep 2.

17. Zannad F., Cannon C.P., Cushman W.C. et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23; 385 (9982): 2067-76. DOI: 10.1016/S0140-6736(14)62225-X. Epub 2015 Mar 10.


For citation:


Khachatryan G.R., Dombrovskii V.S. SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2015;8(2):55-61. (In Russ.) https://doi.org/10.17749/2070-4909.2015.8.2.055-061

Views: 35


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)